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We present preliminary results of influenza vaccine 
effectiveness (VE) in New Zealand using a case test-
negative design for 28 April to 31 August 2014. VE 
adjusted for age and time of admission among all ages 
against severe acute respiratory illness hospital pres-
entation due to laboratory-confirmed influenza was 
54% (95% CI: 19 to 74) and specifically against A(H1N1)
pdm09 was 65% (95% CI:33 to 81). For influenza-con-
firmed primary care visits, VE was 67% (95% CI: 48 to 
79) overall and 73% (95% CI: 50 to 85) against A(H1N1)
pdm09. 
Introduction
The SHIVERS (Southern Hemisphere Influenza and 
Vaccine Effectiveness, Research and Surveillance) 
study [1] has allowed estimation of vaccine effective-
ness (VE) against influenza illness requiring hospi-
talisation since 2012 and against influenza illness 
requiring a primary care consultation (sentinel general 
practices) since 2013. The study captures an ethnically 
diverse urban population of approximately 838,000 
people in Auckland, New Zealand. Patients in the 16 
sentinel general practices are part of the population 
served by the four participating hospitals. VE esti-
mates for 2012 from the hospital arm of the study [2] 
and from both hospital and community arms in 2013 
[3] have been reported previously. Here we report the 
2014 influenza season interim estimates of VE against 
laboratory-confirmed influenza general practice (pri-
mary care) visits and hospitalisations in Auckland, New 
Zealand.
In New Zealand, seasonal trivalent inactivated influ-
enza vaccine is offered annually free of charge to all 
adults aged 65 years and over, pregnant women and all 
individuals over six months of age with chronic medical 
conditions that are likely to increase the severity of the 
infection. Influenza vaccines are also available on the 
private market for all other individuals over six months 
of age. The influenza season usually occurs between 
March and September and the vaccine is available from 
late February.
The influenza strains in the southern hemisphere 
vaccine in 2014 were A/California/7/2009 (H1N1)-
like virus, A/Texas/50/2012 (H3N2)-like virus and B/
Massachusetts/2/2012-like virus (B/Yamagata lineage) 
as recommended by the World Health Organization for 
trivalent influenza vaccines [4].
Methods
Using the case test-negative design to estimate VE as 
previously described [3], we estimated the effective-
ness of seasonal trivalent inactivated influenza vac-
cine against laboratory-confirmed influenza in patients 
hospitalised with severe acute respiratory infections 
(SARI) and in patients presenting to a sentinel general 
practice with an influenza-like illness (ILI) during the 
2014 influenza season. Ethics approval was obtained 
from the Northern A Health and Disability Ethics 
Committee (NTX/11/11/102 AM02).
Patients with SARI or ILI were defined as requiring hos-
pitalisation (SARI) or attending a general practice (ILI) 
with a history of fever or measured temperature ≥38 °C, 
cough and onset within the past 7 days.
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Hospitalised patients were recruited from individuals 
aged six months and older who were admitted to one 
of the four public hospitals covering all the popula-
tion in the study catchment area in south, central and 
east Auckland. Community cases were identified from 
16 sentinel general practices with 103,884 enrolled 
patients selected to be broadly representative of the 
population.
Data collection began on 28 April 2014. Analysis was 
restricted to the influenza season, which defined 
as being from the start of the first two consecutive 
weeks with two or more influenza cases (2 June 2014). 
The interim data collection was until 31 August 2014, 
based on the requirements to complete the analysis in 
time for the World Health Organization strain selection 
meeting in September.
Hospitalised patients were identified following screen-
ing by research nurses of all patients admitted with 
respiratory illness. Patients who gave verbal consent 
completed a case report form and provided a naso-
pharyngeal swab or aspirate for influenza virus testing.
All ILI patients presenting to one of the sentinel general 
practices were screened by the general practitioner or 
practice nurse, and data for all consenting patients 
were entered on an electronic form in the practice man-
agement system. A nasopharyngeal or throat swab was 
collected for influenza virus testing.
A confirmed case of influenza was defined as a 
patient with SARI or ILI with a positive laboratory 
result for any influenza virus detected by real-time 
reverse transcription polymerase chain reaction (rRT-
PCR). Nasopharyngeal and throat swabs were tested 
using the United States Centers for Disease Control 
and Prevention (CDC) rRT-PCR protocol [5]or the 
AusDiagnostic PCR protocol [6]. The two assays per-
form very similarly [3]. rRT-PCR assays detected influ-
enza virus types A and B and subtyped. A convenience 
sample was characterised antigenically using estab-
lished methods [7].
For ILI cases, vaccination status was based on the 
presence or absence of documentation in the general 
practice electronic records of receiving one or more 
doses of the 2014 influenza vaccine, depending on age 
of the participant. Vaccination status in SARI patients 
before hospitalisation was determined by self-report 
of receipt of one or more doses of the 2014 seasonal 
influenza vaccine.
Patients excluded were infants less than 6 months 
of age who are not recommended to be vaccinated, 
those vaccinated less than 14 days before admission 
or presentation and those with symptom onset more 
than seven days before admission or presentation. 
For patients with multiple episodes, the first influenza 
virus-positive episode was used for the analysis or the 
first illness episode if there was no influenza virus-
positive episode.
For all patients, covariates included age, sex, ethnic-
ity, current smoking status and chronic medical condi-
tions. Further data collected on SARI patients included 
a patient- or caregiver-reported measure of depend-
ence (classified as the requirement for assistance with 
normal activities or full dependency on nursing care), 
long-term use of oxygen, low income (using a small 
neighbourhood measure reflecting eight dimensions of 
deprivation [8]), a clinical judgement of obesity and a 
standard self-rated health item scored dichotomously 
as fair or poor versus good, very good or excellent 
overall health [9].
VE is presented for all influenza viruses and A(H1N1)
pdm09. For the SARI dataset, less than 1% (3/519) of 
data were missing for any variable. The ILI dataset had 
no missing values. Interim VE estimates were calcu-
lated from all participants enrolled between 28 April 
and 31 August 2014. Standard logistic regression was 
used to compare the odds of vaccination among influ-
enza-positive versus influenza-negative participants 
for both ILI and SARI, with VE estimated as 100% x (1 
– odds ratio). VE was also calculated adjusting for age 
and the week of the admission or presentation. As a 
sensitivity analysis for the SARI data, a more compre-
hensive adjustment was also carried out, similar to the 
previously reported analysis in 2013 [3]. For this adjust-
ment, we used 2013 data to model the propensity to be 
vaccinated based on all potential confounders. The VE 
was then calculated adjusted for each individual’s pro-
pensity to be vaccinated.
Results
The number of ILI and SARI patients in this study are 
shown by influenza virus status in Figure 1.
A total of 1,272 SARI patients were eligible: all were 
recruited and swabbed for influenza. A total of 1,226 ILI 
patients were recruited, of whom 1,221 were swabbed 
(99.6%).A total of 519 SARI and 919 ILI patients were 
included in the analysis, of whom 148 (29%) and 384 
(42%) were influenza virus positive, respectively 
(Figure 2).
Of the 532 influenza cases detected in both SARI and 
ILI patients, 466 (88%) were type A, with 339 (64%) 
A(H1N1)pdm09, 32 (6%) A(H3N2) and 95 (18%) not sub-
typed (Table 1).
There were 66 (12%) type B detections. Among the 
66 influenza B viruses, 48 were Yamagata lineage, 
one was Victoria lineage, and lineage was not deter-
mined in 17. Of the 48 Yamagata lineage, 25 were anti-
genically typed as B/Massachusetts/2/2012 00-like 
viruses and 23 were not antigenically typed. The one 
B/Victoria lineage virus was antigenically typed as B/
Brisbane/60/2008-like virus.
3www.eurosurveillance.org
Vaccine effectiveness
Of the 148 SARI patients who tested influenza virus 
positive, 35 (24%) were vaccinated, compared with 113 
(30%) of the 371 who tested negative. Of the 384 ILI 
patients who tested influenza virus positive, 37 (10%) 
were vaccinated, compared with 116 (22%) of the 535 
who tested negative (Figure 2).
The proportion vaccinated did not change throughout 
the season. For influenza-confirmed SARI, the crude 
VE for one or more vaccine doses against all circulat-
ing influenza virus strains was 34% (95% confidence 
interval (CI): −3 to 57) (Table 2).
After adjustment for age and week of admission, the 
estimated VE was 54% (95% CI: 19 to 74). The adjusted 
VE for the prevailing circulating subtype, influenza 
A(H1N1)pdm09, was 65% (95% CI: 33 to 81). VE was 
not calculated for other subtypes, or for individuals 
6 months to 17 years of age because of sparse data. 
Adjusted VE against all influenza hospitalisation in the 
18–49-year age group was 46% (95% CI: −42 to 80); in 
the 50–64 year-olds, 74% (95% CI: 23 to 91) and in the 
65 and over age group, 58% (95% CI:−36 to 87). SARI 
influenza-positive cases were significantly more like 
to be young (under five years of age) or old (65 years 
and older) and smokers than were SARI influenza-
negative patients. There was no significant difference 
by chronic disease, sex, income, pregnancy or self-
reported health status. In the SARI sensitivity analysis 
adjusted for the propensity to be vaccinated, the VE for 
all ages was 50% (95% CI: 19 to 69).
For influenza-confirmed ILI cases, the crude VE was 
61% (95% CI: 43 to 74). After adjustment for age and 
week of presentation, the estimated VE was 67% (95% 
CI: 48 to 79). The adjusted VE for the prevailing circulat-
ing subtype, influenza A(H1N1)pdm09, was 73% (95% 
CI: 50 to 85). VE was not calculated for younger peo-
ple or those aged 65 years and over because of sparse 
data. For the 18–49-year age group, the adjusted VE 
was 66% (95% CI: 30 to 84) and in the 50–64 year-
olds, it was 57% (95% CI:−1 to 82).
Discussion
The SHIVERS study allows timely estimation of the 
protective effect of seasonal influenza vaccine in 
the southern hemisphere season. These preliminary 
results suggest that the 2014 vaccine was 54% effec-
tive in preventing hospitalisation for influenza and 
67% effective against presentations to sentinel gen-
eral practices. The 2014 season has been dominated 
to date by the influenza A(H1N1)pdm09 virus. VE was 
similar across adult age groups, although numbers 
were too small for accurate estimates in children and 
elderly people.
The New Zealand seasonal experience is very similar 
to interim VE estimates reported from Canada and the 
United States for the 2013/14 influenza season, when 
the dominant circulating virus was also A(H1N1)pdm09: 
the VE point estimate was 59% for preventing hospital-
isation [10] and 74% for preventing medically attended 
influenza [11] in Canada, while in the United States, 
the interim VE was 61% against medically attended 
Figure 1
Study participants with influenza-like illness (n=1,069) and severe acute respiratory infections (n=642) who were influenza 
positive or negative, by week, New Zealand, 28 April–31 August 2014
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The influenza season began on 2 June 2014 for both influenza-like illness and severe acute respiratory infections. During the season, 384 of 
919 influenza-like illness and 148 of 519 severe acute respiratory infections tested influenza positive.
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Figure 2
Flowchart of all selected, recruited and tested patients with influenza-like illness and severe acute respiratory infection for 
interim influenza vaccine effectiveness analysis, New Zealand, 28 April–31 August 2014
ILI: influenza-like illness; SARI: severe acute respiratory infections.
Recruited sample
     SARI: 1,271
     ILI: 1227
Complete records available by 31 Aug
     SARI: 860
     ILI: 1,157
SARI cases: 642
ILI cases: 1,069
Unique persons
     SARI: 519
     ILI: 919
Influenza positive 
     SARI: 148 (29%)
     ILI: 384 (42%)
Vaccinated 
     SARI: 35 (24%)
     ILI: 37 (10%)
Influenza negative 
     SARI: 371 (71%)
     ILI: 535 (58%)
Vaccinated 
     SARI: 113 (30%)
     ILI: 116 (22%)
Incomplete records:
No vaccination status
     SARI: 15
     ILI: 0
Laboratory result not available by 31 Aug
     SARI: 396
     ILI: 70
Exclusions:
< 6 months of age
     SARI: 140
     ILI: 8
<14 days since vaccination
     SARI: 24
     ILI: 16
>7 days since symptom onset
     SARI: 54
     ILI: 64
Not in influenza season 
     SARI: 120 
     ILI: 127
Unused repeat admissions
     SARI: 3
     ILI: 23
Table 1
Vaccinated and unvaccinated influenza cases by virus type and subtype among hospital (n=519) and general practice 
participants (n=919), New Zealand, 2 June–31 August 2014
Influenza virus type
Hospitalised with  severe acute respiratory infection General practice visits for influenza-like illness
Number vaccinated (%) Number unvaccinated (%) Number vaccinated (%) Number unvaccinated (%)
All 35 (100) 113 (100) 37 (100) 347 (100)
Any Aa 30 (86) 108 (96) 30 (81) 298 (86)
A(H1N1)pdm09 22 (63) 97 (86) 14 (38) 206 (59)
A(H3N2) 7 (20) 7 (6) 4 (11) 14 (4)
All Ba 5 (14) 5 (4) 7 (19) 49 (14)
B/Victoriab 0 0 0 1 (<1)
B/Yamagata lineage 1 (3) 2 (2) 5 (14) 40 (12)
a Not all cases of influenza A and B were subtyped. The number of subtypes does not add up to the number of all influenza A viruses 
identified.
b B/Victoria = B/Victoria lineage-B/Brisbane/60/2008-like.
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influenza [12]. In contrast, the interim VE point esti-
mate from Spain was 44% against all influenza strains, 
and even lower (33%) for the dominant circulating 
virus, A(H1N1)pdm09 [13].
Our interim report has several limitations. Similar to 
other interim VE reports [11], we relied on self-reported 
vaccination status for hospitalised patients. Not all 
laboratory results were available as of 31 August 2014 
(70 ILI, 356 SARI). In addition, the analysis is adjusted 
for only two potential confounders (age and week of 
admission or presentation), although a propensity-
adjusted sensitivity analysis for SARI patients pro-
duced a similar VE estimate. For this interim estimate, 
we were unable to estimate VE for young children with 
two doses of vaccine. We expect to be able to examine 
this and produce stratified VE estimates by age in our 
final season report.
This is the third year we have reported the effective-
ness of trivalent seasonal influenza vaccine in the New 
Zealand setting. We have shown the continued predom-
inance of circulating influenza A(H1N1)pdm09 virus and 
a continued moderate vaccine effectiveness against 
this strain, similar in magnitude to the North American 
estimates for the 2013/14 season. The 2014/15 north-
ern hemisphere seasonal vaccine will contain the same 
components as the 2014 southern hemisphere vaccine 
[14]. These results may thus add useful information 
to consider in preparing for the upcoming northern 
hemisphere influenza season and in selecting strains 
for the next southern hemisphere season.
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Table 2
Estimated influenza vaccine effectiveness, by participant age group and by influenza virus type and subtype: crude plus 
age- and time-adjusted models, New Zealand, 2 June–31 August 2014
Influenza type by age 
group
Influenza positive Influenza negative 
Vaccine effectiveness
Unadjusted Adjusteda
Number 
vaccinated Total %
Number 
vaccinated Total % % 95% CI % 95% CI
SARI
Overall 35 148 24 118 371 32 34 −3 to 57 54 19 to 74
6 months–17 years 4 42 10 15 193 8 NA NA NA NA
18–49 9 58 16 13 52 25 45 −42 to 79 46 −42 to 80
50–64 10 29 34 29 51 57 60 −3 to 84 74 23 to 91
≥65 12 19 63 61 75 81 61 −18 to 87 58 −36 to 87
A(H1N1)pdm09 22 119 18 118 371 32 51 19 to 71 65 33 to 81
ILI
Overall 37 384 10 116 535 22 61 43 to 74 67 48 to 79
6 months–17 years 2 143 1 26 226 12 NA NA NA NA
18–49 years 12 168 7 32 195 16 61 21 to 81 66 30 to 84
50–64 years 12 60 20 26 75 35 53 −4 to 79 57 −1 to 82
≥65 years 11 13 85 32 39 82 NA NA NA NA
A(H1N1)pdm09 all 14 220 6 116 535 22 75 56 to 86 73 50 to 85
A(H1N1)pdm09 ≥65years 1 2 50 32 39 82 NA NA NA NA
CI: confidence interval; ILI: influenza-like illness; NA: not applicable, as there were insufficient data to report VE estimates, SARI: severe acute 
respiratory infections.
a Adjusted for six age groups:  6 months–5 years, 6–17, 18–44, 45–64, 65–79 and ≥80 years and week in the season.
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The 16 participating sentinel general practices from Auckland 
Primary Health Organisation, East Tamaki Health Care and 
ProCare.
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